Gates MRI Commences Phase 3 Clinical Trial For Promising Tuberculosis Vaccine

The Bill & Melinda Gates Medical Research Institute (Gates MRI) has embarked on a significant Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate. This trial, conducted in South Africa, aims to address the substantial health challenge TB presents in the region. A successful outcome could mark the introduction of the first vaccine to prevent pulmonary TB in adolescents and adults in over a century. With TB being a leading global health concern, resulting in 10.6 million infections and 1.3 million deaths in 2022, the stakes are high. The disease disproportionately affects individuals in low- and middle-income countries, exacerbating conditions of poverty, inadequate living conditions, and undernutrition.

In South Africa, where approximately 280,000 people are diagnosed with TB annually, the Phase 3 trial will include up to 20,000 participants across up to 60 sites in seven countries. This double-blind trial will administer either the M72/AS01E vaccine or a placebo to participants, with results expected after up to five years of study, followed by data analysis and regulatory submissions. The M72/AS01E vaccine candidate has been under development since the early 2000s and demonstrated promising efficacy in earlier Phase 2b trials, offering about 50% protection against active pulmonary tuberculosis over three years among Mycobacterium tuberculosis-infected HIV-negative adults.

The Gates MRI is spearheading this trial with backing from the Gates Foundation, Wellcome, and vaccine developer GSK. GSK's contribution includes technical support and supplying the adjuvant component of the vaccine, with commitments to continue post-licensure if successful. Efforts are underway by Gates MRI and its partners to ensure sustainable vaccine access in high-burden areas. This includes collaboration with local communities and stakeholders to formulate a comprehensive plan for long-term access and establishing an international advisory group for program guidance.

The development of an effective TB vaccine is deemed critical, especially as the only existing vaccine, BCG, developed in 1921, fails to provide sufficient protection against pulmonary TB. The M72/AS01E vaccine represents a hopeful advancement in the fight against TB, which has seen setbacks due to the COVID-19 pandemic's impact on control efforts. This initiative not only aims to introduce a new vaccine but also revitalizes global efforts to combat one of the most deadly infectious diseases.